Pulmonary Arterial Hypertension Market Overview, Merger and...

Pulmonary Arterial Hypertension Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2026

Posted 2022-07-07 11:20:29

Government initiatives for Pulmonary arterial hypertension large scale collaborations for technical advancements, the lifestyle habits like smoking and increasing strategic initiatives such as product launch or collaboration are key factors contributing to a high CAGR of Pulmonary arterial hypertension market during the forecast period.

According to the current analysis of Reports and Data, the global Pulmonary arterial hypertension Market was valued at USD 6.02 billion in 2018 and is expected to reach USD 9.27 billion by the year 2026, at a CAGR of 5.6%. Pulmonary arterial hypertension is caused by the rise in pulmonary arterial pressure, which leads to an increase in the workload on the right side of the heart, which progresses the symptoms of PAH (Pulmonary arterial hypertension). The rise in the geriatric population, with the decrease in the levels of immunity, boosts up the market.

The global pulmonary arterial hypertension market is driving due to the prevalence of diseases like (Cirrhosis), Chronic lung diseases like emphysema, Asthma, etc. A person with PAH even can survive without treatment for a long time, but it is essential to treat it as the increased load on the right side of the heart can lead to heart failure. Treatment will help improve the quality of life. Habits such as smoking, tobacco, consumption of alcohol are expected to boost the prevalence of pulmonary arterial hypertension leading to increased demand for the treatment. World Health Organization (WHO) and the Centre for Disease Control and Prevention had suggested that there is a prevalence of PAH that reported 15 to 50 million cases per head. Rise in disease like asthma COPD and chronic lung disorder is expected to rise the PAH market growth. According to the Global Asthma Report 2018 about 1000 people worldwide die of asthma every day and it has affected more than 339 million people. The rise in health care awareness and an increase in medical expenditure is likely to boost the market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2667

The report puts an emphasis on the information regarding the key players with a special focus on their company profile, business overview, recent advancements, product catalog, and strategic business plans. It provides a comprehensive overview of the strategic alliances in the market under taken by the key players such as mergers and acquisitions, joint ventures, collaborations, partnerships, agreements, product launches, brand promotions, and corporate deals, among others.

Key companies operating in the market and profiled in the report include:

Actelion Pharmaceuticals Ltd(Switzerland), Novartis International AG (Switzerland), Gilead Sciences, Inc.(US), United Therapeutics Corporation(US), GlaxoSmithKline Plc. (GSK)(London), Pfizer Inc(US), Dong-A ST Co Ltd (South Korea), Bayer HealthCare(Germany), Merck Sharp & Dohme Corp (US) and Arena P.

Order This Report@ https://www.reportsanddata.com/report-pricing/2667

The Pulmonary Arterial Hypertension market takes into account major geographical locations such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa to offer key insights into market growth, market size, market share, revenue growth, current and emerging trends, supply and demand ratio, import/export, consumer demand and behavior, and presence of key players in each region. The report offers an in-depth country wise analysis to impart better understanding of the market and its growth prospects.

Segments Covered in the report

Product Outlook (Revenue in Million USD; 2016–2026)

Prostacyclin and Prostacyclin Analogs
Soluble Guanylate Cyclase Stimulators
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) Inhibitors
Calcium Channel Blockers
Others

Technology Outlook (Revenue in Million USD; 2016–2026)

Cuff-less BP monitoring devices
Ambulatory monitors
Novel technology smartphones and Bluetooth enabled telemonitoring
Tele-monitoring

Application Outlook (Revenue in Million USD; 2016–2026)

Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase

End-Use Outlook (Revenue in Million USD; 2016–2026)

Hospital
Clinic

Key Regions Analyzed in the Report include:

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- Italy
- France
- BENELUX
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
Latin America
- Brazil
- Rest of LATAM
Middle East & Africa
- Saudi Arabia
- U.A.E.
- South Africa
- Rest of MEA

Furthermore, it consists information about individual segment of the Pulmonary Arterial Hypertension market based on the types and application. The report also offers insights about the key segments expected to register significant revenue growth over the forecast period and primary trends influencing their growth. It also offers CAGR and market share values for each segment to provide clear understanding of demand and trend in the global market.

Further key findings from the report suggest

On the basis of Pulmonary Arterial Hypertension product segment Prostacyclin and Prostacyclin Analogs are expected to boost the market as it functions to improve the vasodilation by preventing platelet activation, they are expected to rise with a CAGR of 5.8%.
Endothelin Receptor Antagonists (ERAs) have been used in the treatment of PAH as is reduces the production of endothelin. Owing to the increase in the cases of PAH, it is likely to reach 5.5% CAGR in the forecast period.
Cicletanine and riociguat are the newly developed therapy of drugs, which has generated more significance in these years as there acts as potent vasodilators that are beneficial for treating severe PAH.
European marketing has given authorization to GSK to expand the indication for Volibris a treatment for pulmonary arterial hypertension, as it was found that the combination of ambrisentan and tadalafil reduced the risk of clinical failure in PAH.
Histone Deacetylation Inhibition (HDAC) is the recent approach for treating PAH, HDAC contributes to pulmonary vascular hypertension, HDAC inhibitors like valproic acid, and suberoylanilide hydroxamic acid inhibits the action of HDAC and further leads to vasodilation.
Cuff-less BP monitoring devices have revolutionized and are also available in now in smartphones and wearables for blood pressure monitoring, and it can be checked with the access of the internet, smartphone applications would help to trace the blood pressure by blood pressure telemonitoring.
Advances in telemonitoring have led to the development of Ambulatory telemetry for hearth monitoring. The patient for monitoring wears this wireless device.Telemetry monitors have traditionally had been used to monitor one or two parameters. However, recent advancements have made it possible to monitor three or four parameters of the heart on an average. The patient just has to wear the device which allows continuous monitoring within the area of coverage.
Calcium channel blockers are widely used in treating hypertension. North America held a major share of the calcium channel blocker market. The rise in the geriatric population and the prevalence of obesity are the major factors that are anticipated to drive the demand for calcium channel blockers during the forecast period.

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2667

Thank you for reading our report. For any specific details on customization of this report, please get in touch with us. We will ensure the report you get is well-suited to your needs.

Browse More Reports:

Pigmentation Disorders Market @ https://www.biospace.com/article/pigmentation-disorders-market-trends-revenue-key-players-growth-share-and-forecast-till-2026/

Pelvic Organ Prolapse Repair Market @ https://www.biospace.com/article/pelvic-organ-prolapse-repair-market-analysis-statistics-revenue-demand-and-trend-analysis-research-report-by-2027/

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W

Head of Business Development

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com